Review: Calprotectin testing differentiates inflammatory bowel disease from the irritable bowel syndrome

Annals of Internal Medicine

Volumn 160, Issue 8, 2014, Pages

  Moayyedi, Paul ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

DIAGNOSTIC TEST; ENDOSCOPY; GASTROINTESTINAL DISEASE; HISTOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; META ANALYSIS (TOPIC); NOTE; POINT OF CARE TESTING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; COLONOSCOPY; ECONOMICS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME;

COLONOSCOPY; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84898870471     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-160-8-201404150-02013     Document Type: Note

References (3)

1. Røseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28:1073-6.
2. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229-39.
3. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70.